Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 76-week Prospective, Open-label, Multicenter Study to Evaluate the Long-term Effect of Rivastigmine Capsule and Transdermal Patch on Worsening of the Underlying Motor Symptoms of PD in Patients With Mild to Moderately Severe Dementia Associated With Parkinson's Disease (PDD)

NCT00623103 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00623103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00623103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 76-week Prospective, Open-label, Multicenter Study to Evaluate the Long-term Effect of Rivastigmine Capsule and Transdermal Patch on Worsening of the Underlying Motor Symptoms of PD in Patients With Mild to Moderately Severe Dementia Associated With Parkinson's Disease (PDD)
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2008
Completion date
Not reported
Enrollment
583 (actual)
Sites
127

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease dementia